SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: stockdoc77 who wrote (50164)2/8/2019 1:42:02 PM
From: immuapproval1 Recommendation

Recommended By
corndog

  Read Replies (1) of 63283
 
Pehl has now accomplished in his short tenure what the G's took years to achieve notably complete managerial incompetence. Going forward what Pehl states must be looked at with extreme skepticism whether due to incompetence or naivete. The notion of immu functioning as a standalone pharma is laughable. There seems to be complete unawareness of why a re-inspection was even being considered and if it was that certainly there would be no AA. Pehl early in the process spoke about being ready with a sales force team because as he implied EARLY AA was a very distinct possibility. After 483 in August he was still no worries as if by hiring a full stable of sales reps AA would be hastened. Really. Actually Behzad could maybe get 25-30 bid here from a real pharma (Roche) who has the chops to develop 132 which immu does not. The problem with this is Behzads ego as he would have to admit that successfully running a bio is a lot more difficult that investing in one. And one other note to Pehl.. the next time you schedule a champagne party invite the FDA and if no RSVP from them I would suggest restocking the champagne. Maybe the sales force can be employed to resell the champagne as there does not seem to be any need for either. Just a thought.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News